Rates and Reasons for Nonuse of Prescription Medication for Inflammatory Bowel Disease in a Referral Clinic

被引:11
作者
Bhasin, Sanchit [1 ]
Singh, Harminder [1 ]
Targownik, Laura E. [1 ]
Israeli, Eran [2 ]
Bernstein, Charles N. [1 ]
机构
[1] Univ Manitoba, Gastroenterol Sect, Dept Internal Med, IBD Clin & Res Ctr, Winnipeg, MB R3E 3P4, Canada
[2] Hadassah Hebrew Univ Hosp, Dept Gastroenterol & Liver Dis, IBD Unit, Jerusalem, Israel
关键词
ulcerative colitis; Crohn's disease; deep remission; inflammatory bowel disease; prescription drugs; CROHNS-DISEASE; ULCERATIVE-COLITIS; POSTOPERATIVE RECURRENCE; TRIAL; METRONIDAZOLE; AZATHIOPRINE; PREVENTION; THERAPY; COHORT; IBSEN;
D O I
10.1097/MIB.0000000000000753
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: We aimed to determine the rates and reasons for nonuse of inflammatory bowel disease (IBD)-specific medication in a referral clinic. Methods: Consecutive persons with Crohn's disease (CD) (n = 423) and ulcerative colitis (UC) (n = 342) were followed in a single clinic over 2 years. At each patient visit, it was determined whether and what type of IBD-specific medications were used at that visit. If medications were not used, the reason for nonuse was recorded. Disease remission, further stratified by "clinical remission" and "deep remission" (clinical remission plus imaging evidence of remission), was considered a reason for nonuse if the attending physician believed the person was in remission and agreed for them to be off medications. Results: Nonuse of IBD-specific medication was seen in 121 persons with CD (29%) and 65 persons with UC (18%). In CD, increased age and disease duration were associated with nonuse; disease phenotype did not predict nonuse. In UC, disease duration was associated with nonuse but age was not. In CD, the most common reason for medication nonuse was deep remission (22.5%), followed by clinical remission (21.4%), not having seen a gastroenterologist for a lengthy period (21.4%) and nonadherence (16%). In UC, nonuse was attributed to deep remission (27.7%), followed by nonadherence (26.3%) and clinical remission (23%). Conclusions: Approximately a quarter of persons with IBD attending at a tertiary care practice do not use IBD-specific medications with a higher rate in CD than UC. The decision not to use medications was deemed appropriate in approximately one-half of all nonusers.
引用
收藏
页码:919 / 924
页数:6
相关论文
共 18 条
[11]  
Miller N H, 1997, Am J Med, V102, P43
[12]   The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era [J].
Morgan, Catharine ;
McBeth, John ;
Cordingley, Lis ;
Watson, Kath ;
Hyrich, Kimme L. ;
Symmons, Deborah P. M. ;
Bruce, Ian N. .
RHEUMATOLOGY, 2015, 54 (10) :1780-1791
[13]   The Manitoba Inflammatory Bowel Disease Cohort Study: a prospective longitudinal evaluation of the use of complementary and alternative medicine services and products [J].
Rawsthorne, Patricia ;
Clara, Ian ;
Graff, Lesley A. ;
Bernstein, Kylie I. ;
Carr, Rachel ;
Walker, John R. ;
Ediger, Jason ;
Rogala, Linda ;
Miller, Norine ;
Bernstein, Charles N. .
GUT, 2012, 61 (04) :521-527
[14]   Fatigue and Health-related Quality of Life in Inflammatory Bowel Disease: Results from a Population-Based Study in the Netherlands: The IBD-South Limburg Cohort [J].
Romberg-Camps, M. J. L. ;
Bol, Y. ;
Dagnelie, P. C. ;
Hesselink-van de Kruijs, M. A. M. ;
Kester, A. D. M. ;
Engels, L. G. J. B. ;
van Deursen, C. ;
Hameeteman, W. H. A. ;
Pierik, M. ;
Wolters, F. ;
Russel, M. G. V. M. ;
Stockbruegger, R. W. .
INFLAMMATORY BOWEL DISEASES, 2010, 16 (12) :2137-2147
[15]   CONTROLLED TRIAL OF METRONIDAZOLE TREATMENT FOR PREVENTION OF CROHNS RECURRENCE AFTER ILEAL RESECTION [J].
RUTGEERTS, P ;
HIELE, M ;
GEBOES, K ;
PEETERS, M ;
PENNINCKX, F ;
AERTS, R ;
KERREMANS, R .
GASTROENTEROLOGY, 1995, 108 (06) :1617-1621
[16]   Strategies in the prevention of post-operative recurrence in Crohn's disease [J].
Rutgeerts, P .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2003, 17 (01) :63-73
[17]   Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology [J].
Silverberg, Mark S. ;
Satsangi, Jack ;
Ahmad, Tariq ;
Arnott, Ian D. R. ;
Bernstein, Charles N. ;
Brant, Steven R. ;
Caprilli, Renzo ;
Colombel, Jean-Frederic ;
Gasche, Christoph ;
Geboes, Karel ;
Jewell, Derek P. ;
Karban, Amir ;
Loftus, Edward V., Jr. ;
Pena, A. Salvador ;
Riddell, Robert H. ;
Sachar, David B. ;
Schreiber, Stefan ;
Steinhart, A. Hillary ;
Targan, Stephan R. ;
Vermeire, Severine ;
Warren, Bryan F. .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 19 :5A-36A
[18]   Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort [J].
Silverstein, MD ;
Loftus, EV ;
Sandborn, WJ ;
Tremaine, WJ ;
Feagan, BG ;
Nietert, PJ ;
Harmsen, WS ;
Zinsmeister, AR .
GASTROENTEROLOGY, 1999, 117 (01) :49-57